Barinthus Biotherapeutics (NASDAQ:BRNS) Posts Quarterly Earnings Results

Barinthus Biotherapeutics (NASDAQ:BRNS) released its quarterly earnings data on Thursday. The company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.28) by $0.02, FiscalAI reports.

Barinthus Biotherapeutics Trading Up 6.0%

Shares of Barinthus Biotherapeutics stock traded up $0.03 during trading on Friday, hitting $0.60. The stock had a trading volume of 34,881 shares, compared to its average volume of 40,767. Barinthus Biotherapeutics has a 12 month low of $0.51 and a 12 month high of $1.83. The firm has a market cap of $24.47 million, a price-to-earnings ratio of -0.58 and a beta of -0.39. The business’s 50-day moving average is $0.64 and its 200 day moving average is $0.64.

Hedge Funds Weigh In On Barinthus Biotherapeutics

A hedge fund recently raised its stake in Barinthus Biotherapeutics stock. Baird Financial Group Inc. lifted its holdings in shares of Barinthus Biotherapeutics PLC Sponsored ADR (NASDAQ:BRNS) by 108.2% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 192,461 shares of the company’s stock after purchasing an additional 100,000 shares during the quarter. Baird Financial Group Inc. owned 0.48% of Barinthus Biotherapeutics worth $179,000 at the end of the most recent quarter. 25.20% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Separately, Weiss Ratings upgraded Barinthus Biotherapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, July 21st. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $4.00.

Barinthus Biotherapeutics Company Profile

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.